142 related articles for article (PubMed ID: 17880765)
21. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patients.
Seminari E; Tinelli C; Minoli L; Sacchi P; Filice G; Zocchetti C; Meneghetti G; Bruno R; Maserati R
Antivir Ther; 2002 Sep; 7(3):175-80. PubMed ID: 12487384
[TBL] [Abstract][Full Text] [Related]
23. The IL-6 system in HIV-1-infection and in HAART-related fat redistribution syndromes.
Saumoy M; López-Dupla M; Veloso S; Alonso-Villaverde C; Domingo P; Broch M; Miranda M; Coll B; Saurí A; Vendrell J; Richart C; Vidal F
AIDS; 2008 Apr; 22(7):893-6. PubMed ID: 18427208
[TBL] [Abstract][Full Text] [Related]
24. [Metabolic syndrome and cardiovascular risk patients under antiretrovirals in a day hospital at Bobo-Dioulasso (Burkina Faso)].
Sawadogo A; Sanou S; Hema A; Kamboule BE; Kabore NF; Sore I; Konate A; Poda GE; Zoungrana J; Sawadogo AB
Bull Soc Pathol Exot; 2014 Aug; 107(3):151-8. PubMed ID: 24953144
[TBL] [Abstract][Full Text] [Related]
25. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients.
Kotler DP
J Acquir Immune Defic Syndr; 2008 Sep; 49 Suppl 2():S79-85. PubMed ID: 18725816
[TBL] [Abstract][Full Text] [Related]
26. Peroxisome proliferator activating receptor alpha and gamma polymorphisms and metabolic abnormalities in HIV-infected patients receiving highly active antiretroviral therapy: the ANRS CO8 APROCO-COPILOTE study.
Nazih H; Raffi F; Taïeb A; Reynes J; Choutet P; Cassuto JP; Ferry T; Chêne G; Leport C; Bard JM;
AIDS Res Hum Retroviruses; 2012 Apr; 28(4):393-9. PubMed ID: 21877956
[TBL] [Abstract][Full Text] [Related]
27. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
Falutz J
Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
[TBL] [Abstract][Full Text] [Related]
28. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy.
Barbaro G
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Aug; 5(4):337-43. PubMed ID: 16101566
[TBL] [Abstract][Full Text] [Related]
29. Lipodystrophy - a sign for metabolic syndrome in patients of the HIV-HEART study.
Potthoff A; Brockmeyer NH; Gelbrich G; Neuhaus K; Esser S; Reinsch N; Hower M; Mostardt S; Neumann A; Neumann T;
J Dtsch Dermatol Ges; 2010 Feb; 8(2):92-8. PubMed ID: 20002869
[TBL] [Abstract][Full Text] [Related]
30. Association between lipodystrophy and length of exposure to ARTs in adult HIV-1 infected patients in Montreal.
Alikhani A; Morin H; Matte S; Alikhani P; Tremblay C; Durand M
BMC Infect Dis; 2019 Sep; 19(1):820. PubMed ID: 31533648
[TBL] [Abstract][Full Text] [Related]
31. Thiazolidinediones in the treatment of HIV/HAART-associated lipodystrophy syndrome.
Edgeworth A; Treacy MP; Hurst TP
AIDS Rev; 2013; 15(3):171-80. PubMed ID: 24002201
[TBL] [Abstract][Full Text] [Related]
32. The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy.
Hansen BR; Petersen J; Haugaard SB; Madsbad S; Obel N; Suzuki Y; Andersen O
HIV Med; 2009 Jul; 10(6):378-87. PubMed ID: 19490178
[TBL] [Abstract][Full Text] [Related]
33. [Cardiovascular risk in HIV infected patients].
Raimundo P; Miranda A; Ribeiro J; Mansinho K
Acta Med Port; 2010; 23(4):669-76. PubMed ID: 20687996
[TBL] [Abstract][Full Text] [Related]
34. Coronary heart disease risks and lifestyle behaviors in persons with HIV infection.
Salyer J; Lyon DE; Settle J; Elswick RK; Rackley D
J Assoc Nurses AIDS Care; 2006; 17(3):3-17. PubMed ID: 16829358
[TBL] [Abstract][Full Text] [Related]
35. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy.
Johnson JA; Albu JB; Engelson ES; Fried SK; Inada Y; Ionescu G; Kotler DP
Am J Physiol Endocrinol Metab; 2004 Feb; 286(2):E261-71. PubMed ID: 14532165
[TBL] [Abstract][Full Text] [Related]
36. Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV type 1-infected patients receiving highly active antiretroviral therapy.
Asensi V; Martín-Roces E; Carton JA; Collazos J; Maradona JA; Alonso A; Medina M; Aburto JM; Martínez E; Rojo C; Bustillo E; Fernández C; Arribas JM
Clin Infect Dis; 2004 Jul; 39(2):240-7. PubMed ID: 15307034
[TBL] [Abstract][Full Text] [Related]
37. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy.
Sevastianova K; Sutinen J; Kannisto K; Hamsten A; Ristola M; Yki-Järvinen H
Am J Physiol Endocrinol Metab; 2008 Jul; 295(1):E85-91. PubMed ID: 18430964
[TBL] [Abstract][Full Text] [Related]
38. Short communication: decreasing soluble CD30 and increasing IFN-gamma plasma levels are indicators of effective highly active antiretroviral therapy.
Sadeghi M; Süsal C; Daniel V; Naujokat C; Zimmermann R; Huth-Kühne A; Opelz G
AIDS Res Hum Retroviruses; 2007 Jul; 23(7):886-90. PubMed ID: 17678471
[TBL] [Abstract][Full Text] [Related]
39. Role of metabolic syndrome and antiretroviral therapy in adiponectin levels and oxidative stress in HIV-1 infected patients.
Morimoto HK; Simão AN; de Almeida ER; Ueda LT; Oliveira SR; de Oliveira NB; Petenucci DL; Panis C; Cecchini R; Dichi I; Reiche EM
Nutrition; 2014; 30(11-12):1324-30. PubMed ID: 25280407
[TBL] [Abstract][Full Text] [Related]
40. [Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients].
Leclercq P; Blanc M
Rev Prat; 2006 May; 56(9):987-94. PubMed ID: 16775979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
